[Immunomodulation therapy for allergic asthma. What is already possible, what is to come?].
Allergic asthma is an immunological disease characterized by certain inflammatory changes in the airways and the lung. Different approaches for immune modulation have been developed to treat this disease. Clinical approved immune modulators include the specific immune therapy (SIT) and treatment with monoclonal antibodies against IgE. Further approaches, like inhibition or modulation of T cell responses, inhibition of effector cytokines or inhibition of cell migration are very interesting but still in development and so far not established for treatment of patients.
Taube
C
C
III. Medizinische Klinik, Schwerpunkt Pneumologie, Johannes Gutenberg Universität, Mainz. taube@3-med.klinik.uni-mainz.de
Buhl
R
R
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D002464:Cell Migration Inhibition / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D000069444:Omalizumab; D010272:Parasitic Diseases / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D000276:Adjuvants, Immunologic; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D007155:Immunologic Factors; D000069444:Omalizumab; D007073:Immunoglobulin E